Helping you make wiser investment decisions

Emerging Leader
Infused Beverage

Market Data
to As of October 8th

  • Current Market Cap
  • Current Bid Price 
  • Current Ask Price
  • Current Share Price
  • 52 Week High
  • 52 Week Low
  • BEV.CN 
  • 36.000M
  • 0.355
  • 0.360
  • 0.360
  • 0.5500
  • 0.1750

Stock Information:

Our unmatched expertise, world-class infrastructure and proven technology enable us to develop and launch premium, innovative, cannabis infused beverages that cater to the next generation of cannabis consumer. Our business is focused on innovation. We produce infused beverages and launch dynamic brands while actively exploring new brand acquisitions, strategic partnerships and joint venture opportunities.

High Capacity Beverage Manufacturing
Near Osoyoos, BC, Canada.

BevCanna offers robust white-label beverage manufacturing capabilities including PET and aluminum form factors available in multiple sizes and custom shapes. Bevcanna’s value proposition is unique within the Canadian infused beverage landscape, boasting not only a proprietary pristine alkaline spring water source, but also robust white-label manufacturing capabilities and the ability to blow its own bottles on-site, a significant cost advantage for the Company, and high barrier to entry for competitors.

Canadian Branded Product

Keef Brands

BevCanna finalized an agreement to act as the exclusive licensee, manufacturing and distribution partner to the award-winning U.S. line of Keef infused beverages for the Canadian market, with product commercialization scheduled to commence imminently. A recent 2020 Headset Insights report confirmed that Keef Brands offers six of the top ten-selling cannabis beverages in Colorado, as well as three of the top ten-selling in California. According to BDSA, Keef Brands ranks second (#2) in the US in units sold amongst all cannabis beverage companies.


BevCanna finalized an agreement with prominent U.S. vape company Bloom and will commercialize high-end extract products under the Cali-Bloom name, with product commercialization scheduled to commence imminently. Bloom is a winner of the Chalice Cup and Cannabis Cup Awards, for both the quality and popularity of their distillate and proprietary strains. Deeply rooted in California, Bloom is consistently one of the top vape brands across multiple major US recreational and medical markets.

Anarchist Mountain & LEV

BevCanna is taking a consumer-centric approach to bringing desired cannabis beverages to market. All product development, branding and sales strategies were informed by our investment in proprietary consumer research. In January 2019, BevCanna conducted quantitative research with over 2,000 non-rejectors of legalized cannabis in California, New York and Canada.


  • Consumer purchase intent
  • Demographic profiles of the consumer target
  • Attitudes towards cannabis beverages in relation to alcohol consumption
  • Insights into consumer desires regarding package format, 25 product concepts, 6 positioning territories

As a result of this study, Anarchist Mountain and LEV were established.

Acquisition of Proven E-Commerce
Platform, Pure Therapy:

BevCanna finalized the acquisition of Pure Therapy, a direct-to-consumer e-commerce company selling a range of natural health products, including nutraceutical and hemp-based cannabidiol products throughout North America and Western Europe. Pure Therapy’s extensive catalogue of formulations are proprietary and professionally crafted based on market demand and product quality. Pure Therapy is a proven e-commerce brand and platform. BevCanna intends to further expand and launch its own CBD proprietary products directly into the global health and wellness market, including the burgeoning U.S. CBD market once an encompassing brand alignment exercise has been completed. Pure Therapy brings an extensive list of over 22,000 customers, acquired since the company’s inception in 2017. The brand has achieved unaudited calendar year 2019 gross revenues of C$4.8M,. BevCanna anticipates strong growth over the next 12 months, achieved through new product integration, acceleration of the growth of the existing natural health products line, and leveraging the extensive e-commerce marketing expertise of the current Pure Therapy team

Capital Structure:

Investment Highlights:

Decades of experience creating, branding and manufacturing iconic brands that resonate with consumers on a global scale

unmatched understanding of consumer preferences and buying behaviour

World class infrastructure, including 40,000-square-foot, HACCP certified manufacturing facility with a current bottling capacity to 210M bottles
per annum

Innovative manufacturing capabilities and processing technology including
custom bottle forms, and water soluble cannabinoids. We deliver a diverse portfolio of product concepts, for both in-house brands and white labeled

292-acre outdoor cultivation site on-site in the fertile Okanagan valley, including access to a pristine alkaline spring water aquifer

Strong path to revenue through multiple streams, including white labeling, B2B ingredient supply, joint ventures, licensing, and brand building.

Executive Team and Board
of Directors:


Certain information in this presentation constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this presentation that are not statements of historical fact are forward-looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend”, “estimate” or the negative of these terms and similar expressions. Forward-looking statements in this presentation include, but are not limited to: statements with respect to: the expansion of the Company’s Okanagan bottling facility up to 170,000 square feet with additional 10,000 square feet completed; that the Company’s outdoor cultivation site produces low-cost, high-quality sun-grown cannabis biomass; the entry into a Canadian joint venture agreement with an established U.S. branded vape company; the entry into a Canadian joint venture agreement with an established U.S. branded infused tea company; the entry into an organic 100-acre cultivation crop sharing agreement with an established Canadian L.P.; the entry into multiple LOIs with LPs for white label manufacturing of beverages; the commercialization of water-soluble beverages and edibles in California; obtaining the necessary regulatory approvals from Health Canada under the Cannabis Act with respect to the production license and the sales license; the submission of second generation branded and licensed products; the launch of test-run of powder-based beverages into U.S. market, through regulated retail in California in September 2019; the timing of cannabis infused product regulations taking effect in Canada in October 2019; submission of ready-to-drink formulations for Anarchist Mountain to Health Canada for approval in October 2019; the launch of LEV powder based beverages into U.S. market in California in November 2019; assuming approval from Health Canada, the launch of Anarchist Mountain Beverages into the Canadian recreational market and submission of LEV products (powder and ready-to-drink) for subsequent approval in the first quarter of 2020; the commencement of white label beverage manufacturing for clients in Canada, based on their formulation submission and approval through Health Canada in the first quarter of 2020; the launch of LEV ready-to-drink products through a multi-national launch strategy across Canada and the US, in addition to extending the distribution of LEV powdered drinks into Canada, in April 2020; the commencement of B2B ingredient sales strategy to strategic U.S. partners, using water soluble powder, in the second quarter of 2020; and the expansion of the Anarchist Mountain brand into vape category in Canada and the U.S. in the second quarter of 2020.

Forward-looking statements are based on certain assumptions regarding: obtaining the necessary regulatory approvals from Health Canada under the Cannabis Act with respect to the production license and the sales license; anticipated changes to the Cannabis Act and the regulations thereunder to permit the production and sale of food products, derivatives and beverages containing THC and CBD; changes to U.S. state and federal laws to permit the production and sale of cannabis and cannabis-derived products; expectations with respect to the future growth of recreational cannabis products; the timely receipt of the required regulatory approvals and other necessary consents; that regulatory requirements will be maintained; general business and economic conditions; the Company’s ability to successfully execute its plans and intentions; the availability of financing on reasonable terms; the Company’s ability to attract and retain skilled staff; the Company’s ability to successfully compete with market competition; and the products and technology offered by the Company’s competitors.

While the Company consider these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements.

The assumptions of the Company, although considered reasonable by it at the time of preparation, may prove to be incorrect. In addition, forward-looking statements necessarily involve known and unknown risks, including, without limitation, the Company not being issued a production license and sales license by Health Canada; Health Canada electing not to legalize and/or permit the production and sale of food products, derivatives and beverages containing THC and CBD; the FDA electing not to legalize and/or permit the production and sale of food products, derivatives and beverages containing CBD; the Company expects to incur significant ongoing costs and obligations relating to its investment in infrastructure, growth, regulatory compliance and operations; the Company is subject to the inherent risks associated with the agricultural business; the Company is vulnerable to rising energy costs; the Company is subject to changes in Canadian laws, regulations and guidelines, which could adversely affect the Company’s future business, financial condition and results of operations; the Company’s intended business in the United States, the characterization, and consequences of that business under federal law, and the framework for the enforcement of cannabis and cannabis related offences in the United States; there is no assurance that the Company will turn a profit or generate revenues; the Company may not be able to effectively manage its growth and operations, which could materially and adversely affect its business; the Company faces competition from other companies where it will conduct business that may have a higher capitalization, more experienced management or may be more mature as a business; if the Company is unable to attract and retain key personnel, it may not be able to compete effectively in the cannabis market; the Company may continue to sell securities for cash to fund operations, capital expansion, mergers and acquisitions that may dilute the current shareholders; the Company currently has insurance coverage; however, because the Company’s business is ancillary to the cannabis industry, there are additional difficulties and complexities associated with such insurance coverage; the Company is currently reliant on a single location, and any adverse changes affecting the Company’s production facility could materially affect the Company’s business and operations; the cultivation of cannabis involves a reliance on a third party cultivator and third party transportation which could result in supply delays, reliability of delivery and other related risks; the Company is reliant on key inputs, such as water and utilities, and any interruption of these services could have a material adverse effect on the Company’s finances and operation results; the Company could be liable for fraudulent or illegal activity by its employees, contractors and consultants resulting in significant financial losses to claims against the Company; the Company’s officers and directors may be engaged in a range of business activities resulting in conflicts of interest; the Company cannot assure that a market will develop or exist for the Common Shares or what the market price of the Common Shares will be; the market price for Common Shares may be volatile and subject to wide fluctuations in response to numerous factors, many of which are beyond the control of the Company; the Company is subject to uncertainty regarding Canadian and United States legal and regulatory status and changes from all levels of government; and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. For more information on the risk, uncertainties and assumptions that could cause anticipated opportunities and actual results to differ materially, please refer to the public filings of the Company which are available on SEDAR at Forward-looking statements contained in this presentation are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.